A Study to Compare Subcutaneous Daratumumab with Intravenous Daratumumab


About this study

The purpose of this study is to evaluate qualtiy of life (QOL) metrics while receiving subcutaneous (SQ) daratumumab, patient satisfaction, and patient preference for IV and/or SC therapies.


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Registration:

  • Age ≥ 18 years old.
  • Diagnosis of multiple myeloma who have not received more than 3 lines of therapy.
  • Currently on treatment with a daratumumab containing combination.
  • Have received at least 4 doses of daratumumab.
  • Intent to convert to SC version of daratumumab.
  • Provide written informed consent.
  • Ability to complete questionnaire(s) by themselves or with assistance.

Exclusion Criteria - Registration:

  • Individuals < 18 years old.
  • Last dose of IV dara received > 90 days prior to day of questionnaire administration.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Open for enrollment

Contact information:

Amy Lam PMP

(507) 266-1475


More information


Publications are currently not available

Mayo Clinic Footer